Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 8.715 USD 0.06% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Aurinia Pharmaceuticals Inc?
Write Note

Aurinia Pharmaceuticals Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aurinia Pharmaceuticals Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Gross Profit
$192.3m
CAGR 3-Years
107%
CAGR 5-Years
N/A
CAGR 10-Years
71%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Gross Profit
$64.9m
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
41%
Repare Therapeutics Inc
NASDAQ:RPTX
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Covalon Technologies Ltd
XTSX:COV
Gross Profit
CA$16.5m
CAGR 3-Years
4%
CAGR 5-Years
-6%
CAGR 10-Years
9%
Spectral Medical Inc
TSX:EDT
Gross Profit
CA$798k
CAGR 3-Years
-17%
CAGR 5-Years
-25%
CAGR 10-Years
-10%
No Stocks Found

Aurinia Pharmaceuticals Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia and currently employs 300 full-time employees. The company went IPO on 2001-07-16. The firm is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The firm has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The company also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

AUPH Intrinsic Value
12.017 USD
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Aurinia Pharmaceuticals Inc's Gross Profit?
Gross Profit
192.3m USD

Based on the financial report for Sep 30, 2024, Aurinia Pharmaceuticals Inc's Gross Profit amounts to 192.3m USD.

What is Aurinia Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
71%

Over the last year, the Gross Profit growth was 29%. The average annual Gross Profit growth rates for Aurinia Pharmaceuticals Inc have been 107% over the past three years , and 71% over the past ten years .

Back to Top